{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27.1","upperLimit":"51.6","value":"44.9"},{"comment":"Upper limit not available due to low number of events","groupId":"OG001","lowerLimit":"26.0","upperLimit":"NA","value":"30.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"57"}],"units":"Participants"}],"description":"Defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of objective tumor progression or to death from any cause, whichever occurs first","dispersionType":"95% Confidence Interval","groups":[{"description":"Palbociclib 125 mg daily and AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestratnt)","id":"OG000","title":"Arm A"},{"description":"AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestrant)","id":"OG001","title":"Arm B"}],"paramType":"MEDIAN","populationDescription":"Patients that achieved confirmed response","reportingStatus":"POSTED","timeFrame":"72 months","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"Months"}